124
Participants
Start Date
May 25, 2018
Primary Completion Date
February 27, 2019
Study Completion Date
February 27, 2019
Abicipar pegol
Abicipar pegol 2 mg administered to the study eye by intravitreal injection on Day 1 and Weeks 4, 8, 16, and 24.
Ophthalmic Consultants of Long Island, Lynbrook
Capital Region Retina, PLLC, Albany
Retina Vitreous Surgeons of Central NY, P.C., Syracuse
Retina Associates of Western New York, Rochester
Pennsylvania Retina Specialists, P.C., Camp Hill
Retina Institute of Virginia, Richmond
Charleston Neuroscience Institute, Ladson
Georgia Retina, P.C., Marietta
Marietta Eye Clinic, Marietta
Retina Specialty Institute, Pensacola
Retina Vitreous Associates of Florida, St. Petersburg
Center for Retina and Macular Disease, Winter Haven
Cincinnati Eye Institute, Cincinnati
Raj K. Maturi, MD, PC, Indianapolis
Black Hills Regional Eye Institute, Rapid City
Gailey Eye Clinic, Bloomington
Sabates Eye Center, Leawood
Texas Retina Associates, Arlington
Strategic Clinical Research Group, LLC, Willow Park
Retinal Consultants of Houston, Houston
Retina Consultants of Houston, The Woodlands
Retinal Consultants of San Antonio, San Antonio
Austin Retina Associates, Austin
Texan Eye, Austin
Retina Research Institute of Texas, Abilene
Premiere Retina Specialists, Midland
Colorado Retina Associates, Golden
Barnet Dulaney Perkins Eye Center, Phoenix
Retina Associates Southwest, PC, Tucson
Sierra Eye Associates, Reno
Win Retina, Arcadia
California Eye Specialists Medical Group, Inc, Pasadena
Mark B. Kislinger, MD, Inc., Glendora
Atlantis Retina Institute (Atlantis Eyecare), Huntington Beach
Retina Consultants of Orange County, Fullerton
N. California Retina Vitreous Associates Medical Group, INC., Mountain View
Retinal Consultants Medical Group, Inc., Sacramento
Lead Sponsor
Allergan
INDUSTRY